label int64 1 1 | id stringlengths 10 12 | original_id stringlengths 8 9 | text stringlengths 347 29.5k |
|---|---|---|---|
1 | 171110556_0 | 171110556 | Intelsat S.A.
Form 20-F
Filed on 08-Mar-2016 Period 31-Dec-2015 Accession number: 0001193125-16-495452
Included Items
1. 20-F 2. EX-1.1 3. EX-2.10 4. EX-2.17 5. EX-2.25 6. EX-3.2 7. EX-4.46 8. EX-4.49 9. EX-8.1 10. EX-12.1 11. EX-13.1 12. EX-15.1 13. XBRL (render)
Table of Contents
UNITED STATES SECURITIES AND EXC... |
1 | 171110556_1 | 171110556 | SUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
¨ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number: 001-35878
INTELSAT S.A.
(Exact name of Registrant as specified in its charter)
N/A
(Translation of Registrant's name into English... |
1 | 171110556_2 | 171110556 |
Title of Each Class
Common Shares, nominal value $0.01 per share 5.75% Series A mandatory convertible junior non-voting preferred shares, nominal value
$0.01 per share
Name of Each Exchange On Which Registered
New York Stock Exchange New York Stock Exchange
Securities registered or to be registered pursuant to Secti... |
1 | 171110556_3 | 171110556 | d) of the Securities Exchange Act of 1934. Yes ¨ No x
Note--checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.
Indicate by check mark whether the registrant (1) has filed al... |
1 | 171110556_b0 | 171110556 | 12,209 (8,671) (33,867) (5,528) (3,165) 53,934 50,769
(1,629,411) (1,887,338) (1,785,701)
720,273
333,133 657,997 (974,246) 25,000 (432) 761,725
639,603
(16,960) 4,178 (355,586)
(174) 271,061
591,762 (487,930) 19,199 2,836,905 29,332 (564,615)
2,000 2,426,653
(335,197) (703,869) 1,862,520 18,405 (1,601) 840,258
... |
1 | 171110556_b1 | 171110556 | 1,389,126) (1,063) (104,656) 167,800 63,144
(44,111) 45,062 (1,024,160) (16,509) 471 (1,039,247) (465) 36,693 131,107 167,800
22,438
64,363
(4,089) (346,799) (424) (351,312)
(5,821) (5,821)
(634) 367,553 (28,423) (1,163)
(8,423) 328,910 (8,372) (8,336) 52,217 43,881
(24,418) 360 3,984 (33,943) (1,069) 12,209 (8,... |
1 | 171111336_0 | 171111336 | ASTRAZENECA PLC
Form 20-F
Filed on 08-Mar-2016 Period 31-Dec-2015 Accession number: 0000950103-16-011733
Included Items
1. 20-F: FORM 20-F 2. EX-1.1: EXHIBIT 1.1 3. EX-7.1: EXHIBIT 7.1 4. EX-8.1: EXHIBIT 8.1 5. EX-12.1: EXHIBIT 12.1 6. EX-12.2: EXHIBIT 12.2 7. EX-13.1: EXHIBIT 13.1 8. EX-15.1: EXHIBIT 15.1 9. EX-15.2... |
1 | 171111336_1 | 171111336 | -15.8: EXHIBIT 15.8 16. EX-15.9: EXHIBIT 15.9
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 ____________________
FORM 20-F
(Mark One)
o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE ... |
1 | 171111336_2 | 171111336 | act name of Registrant as specified in its charter)
England and Wales
(Jurisdiction of incorporation or organization)
2 Kingdom Street, London W2 6BD
(Address of principal executive offices) ___________________
Adrian Kemp AstraZeneca PLC 2 Kingdom Street, London W2 6BD Telephone: +44 20 7604 8000 Facsimile number: ... |
1 | 171111336_3 | 171111336 | Notes due 2020
The New York Stock Exchange
7.000% Notes due 2023
The New York Stock Exchange
3.375% Notes due 2025
The New York Stock Exchange
6.450% Notes due 2037
The New York Stock Exchange
4.000% Notes due 2042
The New York Stock Exchange
4.375% Notes due 2045
The New York Stock Exchange
______________... |
1 | 171111336_b0 | 171111336 | Statements.
We have used the GHG Protocol Corporate Accounting and Reporting Standard (revised edition). Emission factors for electricity have been derived from the International Energy Agency and USEPA eGRID databases and for all other fuels and emission sources from the 2006 IPCC Guidelines for National Greenhouse ... |
1 | 171111336_b1 | 171111336 | . None of the changes are statistically significant. The data quoted in this Annual Report are generated from the revised data. 2 Included in this section are greenhouse gases from direct fuel combustion, process and engineering emissions at our sites and from fuel use in our vehicle fleet. 3 Greenhouse gases from elec... |
1 | 171118582_0 | 171118582 | SPARK NETWORKS INC
Form 10-K
Filed on 11-Mar-2016 Period 31-Dec-2015 Accession number: 0001564590-16-014485
Included Items
1. 10-K 2. EX-10.5(A) 3. EX-21.1 4. EX-23.1 5. EX-23.2 6. EX-31.1 7. EX-31.2 8. EX-32.1 9. XBRL (render)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
x AN... |
1 | 171118582_1 | 171118582 | REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE (State or other jurisdiction of incorporation or organization)
20-8901733 (I.R.S. Employer Identification No.)
11150 Santa Monica Boulevard, Suite 600, Los Angeles, California
(Address of principal executive offices)
90025 (Zip Code)
REGISTRANT'S TELEPHONE NUMBER, ... |
1 | 171118582_2 | 171118582 | the Act. Yes ¨ No x
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to ... |
1 | 171118582_3 | 171118582 | a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of "accelerated filer," "large accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
¨
Accelerated filer
¨
Non-accelerated f... |
1 | 171118582_b0 | 171118582 | unrecognized tax benefits $ 609
Subsequent Events Additional Information
(Detail) - USD ($)
Credit Agreement Subsequent Event [Line Items] Credit facility initiation date Line of credit facility, covenant compliance description
Credit Agreement | Prime Rate Subsequent Event [Line Items] Credit facility, interest rat... |
1 | 171118582_b1 | 171118582 | $ (969)
$ (1,135) $ (2,892)
$ (1,437)
$ (1,127)
$ (12,380)
Basic and diluted net income (loss) per share $ (0.05) $ (0.03) $ 0.00 $ 0.03 $ 0.16 $ (0.04) $ (0.05) $ (0.12) $ (0.06) $ (0.05) $ (0.54)
Shares used in computation of basic net income (loss) per share
25,675 25,188 25,100 24,654 24,425 24,035 23,851 23... |
1 | 171118890_0 | 171118890 | Corindus Vascular Robotics, Inc.
Form 10-K
Filed on 11-Mar-2016 Period 31-Dec-2015 Accession number: 0001387131-16-004549
Included Items
1. 10-K: ANNUAL REPORT 2. EX-21: SUBSIDIARIES OF THE REGISTRANT 3. EX-23: CONSENT OF ERNST & YOUNG 4. EX-31.1: CERTIFICATION OF CHIEF
EXECUTIVE OFFICER 5. EX-31.2: CERTIFICATION OF ... |
1 | 171118890_1 | 171118890 | OR
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 001-37406
CORINDUS VASCULAR ROBOTICS, INC.
(Exact name of Registrant as specified in its charter)
Nevada (State or other jurisdiction of incorporation or organization)
30-0687898 (I.R.S. Employer Identif... |
1 | 171118890_2 | 171118890 | the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes No
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such sh... |
1 | 171118890_3 | 171118890 | 10-K or any amendment to this Form 10-K.
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of th... |
1 | 171118890_b0 | 171118890 | . 30, Mar. 31, Dec. 31, Sep. 30, Jun. 30, Mar. 31, Dec. 31, Dec. 31, Dec. 31, 2015 2015 2015 2015 2014 2014 2014 2014 2015 2014 2013
$ 832 $ 212 $ 909 $ 776 $ 622 $ 554 $ 1,077 $ 730 $ 2,729 $ 2,983 $ 896
1,260 722
941
801
1,670 [1] 793
1,058 1,383 3,724 4,904 2,430
(428) (510) (32) (25)
(1,048) (239) 19
(653)... |
1 | 171118890_b1 | 171118890 | Adjustment For Error Correction Inventory [Member] Cost of revenue
3 Months Ended
12 Months Ended
Dec. 31, Sep. 30, Jun. 30, Mar. 31, Dec. 31, Sep. 30, Jun. 30, Mar. 31, Dec. 31, Dec. 31, Dec. 31, 2015 2015 2015 2015 2014 2014 2014 2014 2015 2014 2013
$ 1,260 $ 722
$ 941 $ 801
$ 1,670
[1] $ 793
$ 1,058 $ 1,383 ... |
1 | 171125007_0 | 171125007 | AVADEL PHARMACEUTICALS PLC
Form 10-K
Filed on 15-Mar-2016 Period 31-Dec-2015 Accession number: 0001144204-16-088149
Included Items
1. 10-K: FORM 10-K 2. EX-10.14: EXHIBIT 10.14 3. EX-10.15: EXHIBIT 10.15 4. EX-10.16: EXHIBIT 10.16 5. EX-10.17: EXHIBIT 10.17 6. EX-10.18: EXHIBIT 10.18 7. EX-10.19: EXHIBIT 10.19 8. EX-... |
1 | 171125007_1 | 171125007 | 15. EX-21.1: EXHIBIT 21.1 16. EX-23.1: EXHIBIT 23.1 17. EX-31.1: EXHIBIT 31.1 18. EX-31.2: EXHIBIT 31.2 19. EX-32.1: EXHIBIT 32.1 20. EX-32.2: EXHIBIT 32.2 21. XBRL (render)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10K
x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECUR... |
1 | 171125007_2 | 171125007 | ieux France (Address of principal executive offices)
69200 (Zip Code)
Registrant's telephone number, including area code: +33 472 78 34 34
Securities registered pursuant to Section 12(b) of the Act:
American Depositary Shares* Ordinary Shares** Title of each class
NASDAQ Global Market Name of exchange on which reg... |
1 | 171125007_3 | 171125007 | ) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically an... |
1 | 171125007_b0 | 171125007 |
Feb. 08, 2016
Subsequent Event [Line Items]
Payments to Acquire Businesses, Gross
FSC Holdings LLC [Member] | Scenario, Forecast [Member]
Subsequent Event [Line Items]
Final Payments to Acquire Business Gross
Total Payments for Business Gross
FSC Holdings LLC [Member] | Subsequent Event [Member]
Subsequent Eve... |
1 | 171125007_b1 | 171125007 | ual) - USD ($) shares in Thousands, $ in
Millions
1 Months Ended
12 Months Ended
Mar. 31, 2014 Feb. 28, 2013 Dec. 31, 2015 Dec. 31, 2014 Dec. 31, 2013
Deerfield Debt Financing [Member]
Repayments of Long-term Lines of Credit
$ 15
Broadfin Debt Financing [Member]
Repayments of Long-term Lines of Credit
5
Senio... |
1 | 171125731_0 | 171125731 | Altisource Portfolio Solutions S.A.
Form 10-K
Filed on 15-Mar-2016 Period 31-Dec-2015 Accession number: 0001628280-16-012704
Included Items
1. 10-K 2. EX-10.60: EXHIBIT 10.60 3. EX-10.61: EXHIBIT 10.61 4. EX-10.62: EXHIBIT 10.62 5. EX-10.63: EXHIBIT 10.63 6. EX-21.1: EXHIBIT 21.1 7. EX-23.1: EXHIBIT 23.1 8. EX-31.1: ... |
1 | 171125731_1 | 171125731 | SECURITIES EXCHANGE ACT OF 1934
FOR THE FISCAL YEAR ENDED DECEMBER 31, 2015
OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 1-34354
ALTISOURCE PORTFOLIO SOLUTIONS S.A.
(Exact name of Registrant as specified in its Charter)
Luxembourg
98-0554932
(S... |
1 | 171125731_2 | 171125731 | rant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o No þ
Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o No þ
Indicate by check mark whether the registrant (1) has filed all reports required to be ... |
1 | 171125731_3 | 171125731 | be contained, to the best of the Registrant's knowledge, in the definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. þ
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated fi... |
1 | 171125731_b0 | 171125731 | .63
Diluted (in dollars per share)
$ (2.35) $ 1.82 $ 2.22 $ 0.18 $ (0.08) $ 1.79 $ 2.24 $ 1.61 $ 2.02 $ 5.69 $ 5.19
Weighted average shares outstanding:
Basic (in shares)
19,196 19,091 19,571 20,172 20,306 21,626 22,089 22,509 19,504 21,625 23,072
Diluted (in shares)
19,196 20,411 20,669 20,995 20,306 23,640 24,... |
1 | 171125731_b1 | 171125731 | ,877
Income (loss) before controlling interests
income
taxes
and
non-
(44,192)
41,200
51,244
4,808
(28)
45,867 58,225 43,201 53,060 147,265 142,333
Net income
(44,351) 37,897 46,846 4,408 (906) 43,115 54,732 40,146 44,800 137,087 133,793
Net income (loss) attributable to Altisource
$ (45,096)
$ 37,046
... |
1 | 171126079_0 | 171126079 | LUXFER HOLDINGS PLC
Form 20-F
Filed on 15-Mar-2016 Period 31-Dec-2015 Accession number: 0001047469-16-011192
Included Items
1. 20-F 2. EX-12.1 3. EX-12.2 4. EX-13.1 5. EX-13.2 6. EX-15.1 7. EX-15.2 8. EX-16.1
Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS... |
1 | 171126079_1 | 171126079 |
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number 001-35370
LUXFER HOLDINGS PLC
(Exact name of Registrant as specified in its charter)
England and Wales ... |
1 | 171126079_2 | 171126079 | value £0.50 each
New York Stock Exchange*
American Depositary Shares, each representing an Ordinary Share of nominal value £0.50 each
New York Stock Exchange
Securities registered or to be registered pursuant to Section 12(g) of the Act: None
Securities for which there is a reporting obligation pursuant to Sectio... |
1 | 171126079_3 | 171126079 | filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ý No o
Indicate by che... |
1 | 171126079_b0 | 171126079 | , Long-Term Umbrella Incentive Plan, Non-Executive Directors Equity Incentive Plan, Executive Officer IPO Stock Option Grants and Non-Executive Director IPO Stock Option Grants of Luxfer Holdings PLC (the "Company") and in the Registration Statement on Form S-8 (No. 333-196166) pertaining to the Employee Stock Purchase... |
1 | 171126079_b1 | 171126079 | (b) of Section 1350, Chapter 63 of Title 18, United States Code)
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of Luxfer Holdings PLC, a public limited company incorporated under English ... |
1 | 171129104_0 | 171129104 | Adaptimmune Therapeutics PLC
Form 20-F
Filed on 17-Mar-2016 Period 31-Dec-2015 Accession number: 0001104659-16-105686
Included Items
1. 20-F 2. EX-4.3 3. EX-4.4 4. EX-4.28 5. EX-4.29 6. EX-4.30 7. EX-4.31 8. EX-4.32 9. EX-4.33 10. EX-4.34 11. EX-4.35 12. EX-4.36 13. EX-12.1 14. EX-12.2 15. EX-13.1 16. EX-13.2 17. EX-... |
1 | 171129104_1 | 171129104 | ACT OF 1934
OR
x TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from July 1, 2015 to December 31, 2015
OR
o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number 001-37368
ADAPTIMMUNE T... |
1 | 171129104_2 | 171129104 | , Oxfordshire OX14 4RY United Kingdom (44) 1235 430000
Facsimile: (44) 1235 430001 james.noble@adaptimmune.com (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)
Securities registered or to be registered pursuant to Section 12(b) of the Act:
Title of each class American Depositary... |
1 | 171129104_3 | 171129104 | o Yes x No
If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. o Yes x No
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Secti... |
1 | 171129104_b0 | 171129104 | the "Form 20-F") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and
2. The information contained in the Form 20-F fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: March 17, 2016
/s/ Ja... |
1 | 171129104_b1 | 171129104 | ):
a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information and
b. any fraud, whether or not material, that involv... |
1 | 171129120_0 | 171129120 | Innocoll Holdings Plc
Form 20-F
Filed on 17-Mar-2016 Period 31-Dec-2015 Accession number: 0001571049-16-013110
Included Items
1. 20-F: FORM 20-F 2. EX-4.14: EXHIBIT 4.14 3. EX-4.15: EXHIBIT 4.15 4. EX-4.16: EXHIBIT 4.16 5. EX-4.19: EXHIBIT 4.19 6. EX-4.20: EXHIBIT 4.20 7. EX-12.1: EXHIBIT 12.1 8. EX-12.2: EXHIBIT 12.... |
1 | 171129120_1 | 171129120 |
OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR
ENDED DECEMBER 31, 2015
OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
OR ¨ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF... |
1 | 171129120_2 | 171129120 | Shares, $0.01 par value per share
NASDAQ Global Market
Securities registered or to be registered pursuant to Section 12(g) of the Act. None
(Title of Class)
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act. None
(Title of Class)
Indicate the number of outstanding shares of e... |
1 | 171129120_3 | 171129120 | Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes ¨ No
Indicate by check mark whether the registrant has submitted electronically and posted ... |
1 | 171129120_b0 | 171129120 | or other employees who have a significant role in the registrant's internal control over financial reporting.
/s/ Jose Carmona Chief Financial Officer
(Principal Financial Officer)
Dated: March 17, 2016
Exhibit 13.1
CERTIFICATION PURSUANT TO RULE 13a-14(b)/RULE 15d-14(b)UNDER THE EXCHANGE ACT
AND 18 U.S.C. SECTION 1... |
1 | 171129120_b1 | 171129120 | reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
(c) Evaluated the effectiveness of the registrant's disclosure ... |
1 | 171135847_0 | 171135847 | Cellectis S.A.
Form 20-F
Filed on 21-Mar-2016 Period 31-Dec-2015 Accession number: 0001193125-16-512098
Included Items
1. 20-F 2. EX-4.5.1 3. EX-4.16 4. EX-4.17 5. EX-8.1 6. EX-12.1 7. EX-12.2 8. EX-13.1 9. EX-13.2 10. EX-15.1
Table of Contents
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 2054... |
1 | 171135847_1 | 171135847 | 1934
OR
¨ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number 001-36891
CELLECTIS S.A.
(Exact name of Registrant as specified in its charter and translation of Registrant's name into English)
France
(Jurisdiction of incorporation or organization)
Cellect... |
1 | 171135847_2 | 171135847 | 0.05 per share*
Name of each exchange on which registered
Nasdaq Global Market
Nasdaq Global Market*
*Not for trading, but only in connection with the registration of the American Depositary Shares.
Securities registered or to be registered pursuant to Section 12(g) of the Act.
None
Securities for which there is ... |
1 | 171135847_3 | 171135847 | 1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate b... |
1 | 171135847_b0 | 171135847 | requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: March 21, 2016
/s/ André Choulika Name: André Choulika Title: Chief Executive ... |
1 | 171135847_b1 | 171135847 |
affect the Company's ability to record, process, summarize and report financial information and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial
reporting.
Date: March 21, 2016
/s/ Eric Dutang Name: Eri... |
1 | 171136143_0 | 171136143 | Yandex N.V.
Form 20-F
Filed on 22-Mar-2016 Period 31-Dec-2015 Accession number: 0001047469-16-011404
Included Items
1. 20-F 2. EX-1.2 3. EX-7.3 4. EX-8.1 5. EX-12.1 6. EX-12.2 7. EX-13.1 8. EX-15.1 9. XBRL (render)
Use these links to rapidly review the document TABLE OF CONTENTS YANDEX N.V. INDEX TO CONSOLIDATED FI... |
1 | 171136143_1 | 171136143 | year ended December 31, 2015
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from
to
OR
SHELL COMPANY PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report
Commission file num... |
1 | 171136143_2 | 171136143 |
Securities registered or to be registered pursuant to Section 12(b) of the Act.
Title of each class Class A Ordinary Shares
Name of each exchange on which registered
NASDAQ Global Select Market
Securities registered or to be registered pursuant to Section 12(g) of the Act. None
Securities for which there is a rep... |
1 | 171136143_3 | 171136143 | to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months ... |
1 | 171136143_b0 | 171136143 | paid for acquisitions Subsequent event Subsequent events Aggregate principal amount of outstanding notes repurchased and retired Subsequent event | 200 Labs Inc Subsequent events Ownership interest acquired (as a percent) Investment amount Investment amount paid at closing Investment cost to be paid in installments Nu... |
1 | 171136143_b1 | 171136143 | Y TRANSACTIONS (Details) $ / shares in Units, RUB in
Millions, $ in Millions
Major shareholders | Class A RELATED-PARTY TRANSACTIONS Number of shares registered in a public offering by shareholders Number of shares sold pursuant to an option granted to the underwriters Share price (in dollars per share) | $ / shares Ex... |
1 | 171137793_0 | 171137793 | Biotie Therapies Corp.
Form 20-F
Filed on 22-Mar-2016 Period 31-Dec-2015 Accession number: 0000950103-16-012042
Included Items
1. 20-F: FORM 20-F 2. EX-12.1: EXHIBIT 12.1 3. EX-12.2: EXHBIIT 12.2 4. EX-13.1: EXHIBIT 13.1 5. EX-13.2: EXHIBIT 13.2 6. EX-15.1: EXHBIT 15.1
UNITED STATES SECURITIES AND EXCHANGE COMMISSI... |
1 | 171137793_1 | 171137793 | SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from
to
.
OR
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report
Commission file number: 001-37423
Biotie Therapies Oyj
(Exact name of R... |
1 | 171137793_2 | 171137793 | (b) of the Act:
Title of each class
Name of each exchange on which registered
American Depositary Shares, each representing 80 Ordinary Shares, no par value
The NASDAQ Global Select Market
Ordinary Shares, no par value
The NASDAQ Global Select Market*
* Not listed for trading, only in connection with the listing... |
1 | 171137793_3 | 171137793 | Securities Exchange Act of 1934. Yes No
Note Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.
Indicate by check mark whether the registrant (1) has filed all reports ... |
1 | 171137793_b0 | 171137793 | a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the "Exchange Act") and Section 1350 of Chapter 63 of Title 18 of the United States Code.
Timo Veromaa, President and Chief Executive Officer of Biotie Therapies Corp., certifies that, to the best of his knowledge:
1.
the Report fully complies with th... |
1 | 171137793_b1 | 171137793 | occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting.
5.
The company's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over fin... |
1 | 171138558_0 | 171138558 | Akari Therapeutics Plc
Form 10-K
Filed on 23-Mar-2016 Period 31-Dec-2015 Accession number: 0001144204-16-089697
Included Items
1. 10-K 2. EX-21.1: EXHIBIT 21.1 3. EX-23.1: EXHIBIT 23.1 4. EX-31.1: EXHIBIT 31.1 5. EX-31.2: EXHIBIT 31.2 6. EX-32: EXHIBIT 32 7. XBRL (render)
UNITED STATES SECURITIES AND EXCHANGE COMMI... |
1 | 171138558_1 | 171138558 | 001-36288
AKARI THERAPEUTICS, PLC (Exact name of registrant as specified in its charter)
England and Wales (State or other jurisdiction of incorporation or organization)
98-1034922 (I.R.S. Employer Identification No.)
24 West 40th Street, 8th Floor New York, NY 10018
(Address of principal executive offices)
(646)... |
1 | 171138558_2 | 171138558 | x
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requir... |
1 | 171138558_3 | 171138558 | ated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer ¨
Accelerated filer ¨
Non-accelerated filer ¨ [Do not check if a smaller reporting company]
Smalle... |
1 | 171138558_b0 | 171138558 | Percent 20.25%
21.50%
Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total | £
£ 1,033,484
Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total
14.50%
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards
$ 15,643,618
Foreign Tax... |
1 | 171138558_b1 | 171138558 |
Deferred tax assets/liabilities $ 0
$ 0
Taxes (Details 4)
Dec. 31, 2015 USD ($)
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
2016
$ 0
2017
0
2018
0
2019
0
2020
0
Beyond 2020
15,643,618
Total operating loss carry forwards
15,643,618
Foreign Tax Authority [Member]
Opera... |
1 | 171144445_0 | 171144445 | Presbia PLC
Form 10-K
Filed on 28-Mar-2016 Period 31-Dec-2015 Accession number: 0001564590-16-015335
Included Items
1. 10-K 2. EX-21.1 3. EX-23.1 4. EX-23.2 5. EX-31.1 6. EX-31.2 7. EX-32.1 8. XBRL (render)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-K
(Mark One)
x ANNUAL REPOR... |
1 | 171144445_1 | 171144445 | of incorporation or organization)
120/121 Baggot Street Lower Dublin 2 Ireland
(Address of principal executive offices, including zip code)
Registrant's Telephone Number, Including Area Code: +353 (1) 659 9446
98-1162329 (IRS Employer Identification No.)
Securities registered pursuant to Section 12(b) of the Act:
... |
1 | 171144445_2 | 171144445 | to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of ... |
1 | 171144445_3 | 171144445 |
o
Non-accelerated filer
o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
Accelerated filer
¨
Smaller reporting company
x
The aggregate market value of the Registrant's ordinary shares (the only common equity of the Registrant) held by... |
1 | 171144445_b0 | 171144445 | Income tax provision
1
9
4
5
5
3
2
19
10
Net loss
$ (3,349)
$ (4,900)
$ (5,319)
$ (4,593)
$ (2,946)
$ (3,052)
$ (6,894) $ (2,772)
$ (18,161)
$ (15,664)
Net loss per share - basic and diluted
$ (0.25) $ (0.37) $ (0.40) $ (0.39) $ (0.32) $ (0.33) $ (0.75) $ (0.30) $ (1.40) $ (1.71)
Weighted average,... |
1 | 171144445_b1 | 171144445 | ,016 1,675 732
7,935 4,243
Sales and marketing
593
760
834
519
546
463
394
249
2,706 1,652
General and administrative
1,391 1,762 2,007 2,319 1,048 881
4,272 1,376 7,479 7,577
Operating loss
(3,348) (4,879) (5,315) (4,588) (2,394) (2,328) (6,313) (2,337) (18,130) (13,372)
Interest expense
552
719
58... |
1 | 171156221_0 | 171156221 | Proqr Therapeutics N.V.
Form 20-F
Filed on 31-Mar-2016 Period 31-Dec-2015 Accession number: 0001193125-16-525912
Included Items
1. 20-F: FORM 20-F 2. EX-8.1 3. EX-12.1 4. EX-12.2 5. EX-13.1 6. EX-15.1
Table of Contents
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 20-F
(Mark One)
¨... |
1 | 171156221_1 | 171156221 | OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report: Not applicable
For the transition period from
to
Commission file number 001-36622
PROQR THERAPEUTICS N.V.
(Exact name of Registrant as specified in its charter)
The Netherlands
(Jurisdiction of incorporation or org... |
1 | 171156221_2 | 171156221 | Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None
(Title of Class)
Indicate the number of outstanding shares of each of the issuer's classes of capital or common stock as of the close of the period covered by the annual report. Ordinary shares, nominal value 0.04 per shar... |
1 | 171156221_3 | 171156221 | file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes ¨ No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regu... |
1 | 171156221_b0 | 171156221 | significant role in the Company's internal control over financial reporting.
Date: March 31, 2016
By: /S/ Smital Shah Name: Smital Shah Title: Chief Financial Officer (Principal Financial Officer)
Exhibit 13.1
Certification by the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350... |
1 | 171156221_b1 | 171156221 | , or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles (c) Evaluated th... |
1 | 171157060_0 | 171157060 | Voxeljet AG
Form 20-F
Filed on 01-Apr-2016 Period 31-Dec-2015 Accession number: 0001047469-16-011821
Included Items
1. 20-F 2. EX-8.1 3. EX-12.1 4. EX-12.2 5. EX-12.3 6. EX-12.4
Use these links to rapidly review the document TABLE OF CONTENTS voxeljet AG INDEX TO FINANCIAL STATEMENTS
Table of Contents
As filed with... |
1 | 171157060_1 | 171157060 | ITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
o
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number 001-36130
voxeljet AG
(Exact name of Registrant as specified in its charter)
Not Applicable (Translation of Re... |
1 | 171157060_2 | 171157060 | an ordinary share
Ordinary shares, 1.00 nominal value per share*
Name of each exchange on which registered New York Stock Exchange LLC New York Stock Exchange LLC*
*
Not for trading purposes, but only in connection with the registration of American Depositary Shares pursuant to the requirements of the Securities an... |
1 | 171157060_3 | 171157060 |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing require... |
1 | 171157060_b0 | 171157060 | Report"), the undersigned, Dr. Ingo Ederer, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended and
(2) The information contained in the Report... |
1 | 171157060_b1 | 171157060 | of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's in... |
1 | 171162302_0 | 171162302 | Uniqure N.V.
Form 20-F
Filed on 04-Apr-2016 Period 31-Dec-2015 Accession number: 0001047469-16-011896
Included Items
1. 20-F 2. EX-8.1 3. EX-12.1 4. EX-12.2 5. EX-13.1 6. EX-15.1
Use these links to rapidly review the document TABLE OF CONTENTS UNIQURE N.V. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Table of Content... |
1 | 171162302_1 | 171162302 | URITIES EXCHANGE ACT OF 1934
For the transition period from
to
o
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report
Commission file number: 001-36294
uniQure N.V.
(Exact name of Registrant as specified in its charter and t... |
1 | 171162302_2 | 171162302 | is a reporting obligation pursuant to Section 15(d) of the Act: Ordinary Shares
Name of each exchange on which registered NASDAQ Global Select Market
Indicate the number of outstanding shares of each of the issuer's classes of capital or common stock as of the close of the period covered by the annual report: 24,327... |
1 | 171162302_3 | 171162302 | has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post suc... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.